SG11201401007SA - Compositions and methods for toxigenicity testing - Google Patents
Compositions and methods for toxigenicity testingInfo
- Publication number
- SG11201401007SA SG11201401007SA SG11201401007SA SG11201401007SA SG11201401007SA SG 11201401007S A SG11201401007S A SG 11201401007SA SG 11201401007S A SG11201401007S A SG 11201401007SA SG 11201401007S A SG11201401007S A SG 11201401007SA SG 11201401007S A SG11201401007S A SG 11201401007SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- toxigenicity
- testing
- toxigenicity testing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161540693P | 2011-09-29 | 2011-09-29 | |
| PCT/US2012/057825 WO2013049508A1 (en) | 2011-09-29 | 2012-09-28 | Compositions and methods for toxigenicity testing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401007SA true SG11201401007SA (en) | 2014-04-28 |
Family
ID=47996425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401007SA SG11201401007SA (en) | 2011-09-29 | 2012-09-28 | Compositions and methods for toxigenicity testing |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9217172B2 (en) |
| EP (1) | EP2761065B1 (en) |
| JP (1) | JP5877617B2 (en) |
| KR (1) | KR101640694B1 (en) |
| CN (1) | CN103958747B (en) |
| AU (1) | AU2012315783B2 (en) |
| BR (1) | BR112014007717B1 (en) |
| CA (1) | CA2850531C (en) |
| ES (1) | ES2653249T3 (en) |
| HK (1) | HK1199911A1 (en) |
| HR (1) | HRP20171937T1 (en) |
| HU (1) | HUE037509T2 (en) |
| IL (1) | IL231768B (en) |
| LT (1) | LT2761065T (en) |
| MX (1) | MX348188B (en) |
| PL (1) | PL2761065T3 (en) |
| RU (1) | RU2616281C2 (en) |
| SG (1) | SG11201401007SA (en) |
| SI (1) | SI2761065T1 (en) |
| WO (1) | WO2013049508A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3014267T (en) | 2013-06-28 | 2018-12-10 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
| EP3742165B1 (en) | 2013-08-09 | 2023-06-21 | BioMadison, Inc. | Botulinum toxin assay with improved sensitivity |
| ES2642916T3 (en) | 2014-06-06 | 2017-11-20 | Galit KLEINER-FISMAN | Botulinum toxin for use in the treatment of paratonia |
| WO2016102068A1 (en) | 2014-12-23 | 2016-06-30 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| EP3423084B1 (en) | 2016-03-02 | 2021-09-01 | Merz Pharma GmbH & Co. KGaA | Composition comprising botulinum toxin |
| EP3679946B1 (en) | 2016-05-27 | 2022-01-05 | Ipsen Biopharm Limited | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine |
| TWI737742B (en) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | Botulinum toxin prefilled syringe system, kit having the same and use thereof |
| EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
| US10751394B2 (en) * | 2016-10-25 | 2020-08-25 | Cellsnap Llc | Neurotoxins and uses thereof |
| EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
| EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| JP7007392B2 (en) | 2017-03-24 | 2022-01-24 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | Improved use of botulinum neurotoxin in the treatment of sialadenitis |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| ES2930237T3 (en) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | New recombinant botulinum neurotoxins with longer duration of effects |
| EP3700919A1 (en) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| EP3713595A1 (en) | 2017-11-22 | 2020-09-30 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
| WO2020070017A1 (en) | 2018-10-02 | 2020-04-09 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
| JP2022514151A (en) | 2018-10-08 | 2022-02-10 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | Neurotoxin prefilled vial |
| JP2022521237A (en) | 2019-02-21 | 2022-04-06 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | New uses of botulinum neurotoxin for the treatment of tremor |
| KR102297991B1 (en) * | 2019-10-11 | 2021-09-07 | 주식회사 하울바이오 | Anti-Syntaxin 1A antibodies inhibiting SNARE complex and use thereof |
| CN115666629A (en) | 2020-06-05 | 2023-01-31 | 莫茨药物股份两合公司 | High dose and low volume botulinum toxin treatment of facial wrinkles |
| CN113774023B (en) * | 2021-09-28 | 2022-11-25 | 中国食品药品检定研究院 | Construction of human induced pluripotent stem cell induced differentiation nerve cell evaluation model and application of model in evaluation of drug neurotoxicity |
| US20230225954A1 (en) | 2022-01-14 | 2023-07-20 | Galderma Holding SA | Treatment of moderate to very severe glabellar lines and lateral canthal lines |
| TW202400223A (en) | 2022-02-15 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | Liquid formulation preparing method and use thereof |
| TW202348248A (en) | 2022-02-15 | 2023-12-16 | 德商梅茲製藥有限兩合公司 | Liquid formulation prepariing method and use thereof |
| TW202400122A (en) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | Use of botulinum toxin for reduction of skin pore size and/or sebum production, and method for reduction of skin pore size and/or sebum production |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| AU758455B2 (en) * | 1997-07-21 | 2003-03-20 | Arpi Matossian-Rogers | Ligands, including antibodies, showing reactivity against endocrine cells |
| US7115399B2 (en) | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| US6984375B2 (en) | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| GB2398636A (en) | 2003-02-21 | 2004-08-25 | Ipsen Ltd | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
| EP2332959B1 (en) | 2003-12-19 | 2014-11-26 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| US7598027B2 (en) * | 2004-02-24 | 2009-10-06 | Allergan, Inc. | Botulinum toxin screening assays |
| GB2416849A (en) | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample |
| DE102005019302A1 (en) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier for targeting nerve cells |
| WO2008008082A2 (en) | 2005-09-19 | 2008-01-17 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
| US8949033B2 (en) | 2006-04-28 | 2015-02-03 | The Chemo-Sero-Therapeutic Research Institute | Method for quantification of neurotoxin |
| US8067192B2 (en) * | 2007-06-05 | 2011-11-29 | City Of Hope | Methods for detection of botulinum neurotoxin |
| CA2708780A1 (en) * | 2007-12-11 | 2009-06-18 | Research Development Foundation | Small molecules for neuronal differentiation of embryonic stem cells |
| EP3095470A1 (en) * | 2008-02-07 | 2016-11-23 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
| ES2524312T3 (en) | 2008-03-14 | 2014-12-05 | Allergan, Inc. | Assays of immunotype-based botulinum toxin serotype A activity |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| EP2191847A1 (en) * | 2008-11-19 | 2010-06-02 | Merz Pharma GmbH & Co.KGaA | Method for preparing compositions comprising a protein, water and glycerol |
| JP6189581B2 (en) * | 2009-02-20 | 2017-08-30 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | Methods and compositions for stem cell differentiation |
| JP5816100B2 (en) * | 2009-02-27 | 2015-11-18 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | Pluripotent cell differentiation |
| MX2011009621A (en) * | 2009-03-13 | 2011-12-16 | Allergan Inc | Cells useful for immuno-based botulinum toxin serotype a activity assays. |
| CN102612562A (en) * | 2009-08-27 | 2012-07-25 | 色奈普提科研究有限公司 | A novel protein delivery system to generate induced pluripotent stem (ips) cells or tissue-specific cells |
| JP5885255B2 (en) | 2009-08-28 | 2016-03-15 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | Identification of genetic variation in affected tissues |
| ES2539487T3 (en) | 2009-11-04 | 2015-07-01 | Cellular Dynamics International, Inc. | Episomic reprogramming with chemical compounds |
| US9096886B2 (en) | 2011-03-11 | 2015-08-04 | Merz Pharma Gmbh & Co. Kgaa | Method for the determination of botulinum neurotoxin biological activity |
| EP2694644B1 (en) * | 2011-03-30 | 2018-01-24 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| WO2013102088A2 (en) * | 2011-12-31 | 2013-07-04 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| AU2013229472A1 (en) * | 2012-03-07 | 2014-08-07 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determining neurotoxin activity based on a modified luciferase |
| US8778623B2 (en) * | 2012-09-14 | 2014-07-15 | Wisconsin Alumni Research Foundation | Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin |
| US9102901B2 (en) * | 2012-12-20 | 2015-08-11 | Rohm And Haas Electronic Materials Llc | Methods and compositions for removal of metal hardmasks |
-
2012
- 2012-09-28 KR KR1020147011026A patent/KR101640694B1/en active IP Right Grant
- 2012-09-28 WO PCT/US2012/057825 patent/WO2013049508A1/en active Application Filing
- 2012-09-28 MX MX2014003874A patent/MX348188B/en active IP Right Grant
- 2012-09-28 EP EP12835606.0A patent/EP2761065B1/en active Active
- 2012-09-28 JP JP2014533369A patent/JP5877617B2/en active Active
- 2012-09-28 SI SI201231169T patent/SI2761065T1/en unknown
- 2012-09-28 LT LTEP12835606.0T patent/LT2761065T/en unknown
- 2012-09-28 BR BR112014007717-7A patent/BR112014007717B1/en active IP Right Grant
- 2012-09-28 SG SG11201401007SA patent/SG11201401007SA/en unknown
- 2012-09-28 CN CN201280053513.8A patent/CN103958747B/en active Active
- 2012-09-28 PL PL12835606T patent/PL2761065T3/en unknown
- 2012-09-28 US US14/347,074 patent/US9217172B2/en active Active
- 2012-09-28 AU AU2012315783A patent/AU2012315783B2/en active Active
- 2012-09-28 RU RU2014117161A patent/RU2616281C2/en active
- 2012-09-28 ES ES12835606.0T patent/ES2653249T3/en active Active
- 2012-09-28 CA CA2850531A patent/CA2850531C/en active Active
- 2012-09-28 HU HUE12835606A patent/HUE037509T2/en unknown
-
2014
- 2014-03-27 IL IL231768A patent/IL231768B/en active IP Right Grant
-
2015
- 2015-01-09 HK HK15100273.1A patent/HK1199911A1/en unknown
-
2017
- 2017-12-14 HR HRP20171937TT patent/HRP20171937T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014003874A (en) | 2014-08-18 |
| EP2761065B1 (en) | 2017-12-06 |
| ES2653249T3 (en) | 2018-02-06 |
| CN103958747A (en) | 2014-07-30 |
| EP2761065A1 (en) | 2014-08-06 |
| HK1199911A1 (en) | 2015-07-24 |
| PL2761065T3 (en) | 2018-02-28 |
| KR101640694B1 (en) | 2016-07-18 |
| LT2761065T (en) | 2018-01-10 |
| KR20140086981A (en) | 2014-07-08 |
| US9217172B2 (en) | 2015-12-22 |
| IL231768B (en) | 2019-06-30 |
| JP2014528724A (en) | 2014-10-30 |
| IL231768A0 (en) | 2014-05-28 |
| WO2013049508A1 (en) | 2013-04-04 |
| AU2012315783B2 (en) | 2015-08-20 |
| HRP20171937T1 (en) | 2018-02-09 |
| EP2761065A4 (en) | 2015-05-06 |
| SI2761065T1 (en) | 2018-02-28 |
| AU2012315783A1 (en) | 2014-04-17 |
| BR112014007717B1 (en) | 2021-07-20 |
| RU2616281C2 (en) | 2017-04-13 |
| MX348188B (en) | 2017-06-01 |
| US20140234857A1 (en) | 2014-08-21 |
| JP5877617B2 (en) | 2016-03-08 |
| CA2850531A1 (en) | 2013-04-04 |
| HUE037509T2 (en) | 2018-09-28 |
| CN103958747B (en) | 2017-03-01 |
| RU2014117161A (en) | 2015-11-10 |
| CA2850531C (en) | 2016-06-07 |
| BR112014007717A2 (en) | 2017-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1199911A1 (en) | Compositions and methods for toxigenicity testing | |
| IL272539B (en) | Compositions and methods for immunotherapy | |
| HK1246715A1 (en) | Compositions and methods for targeted thermomodulation | |
| HK1202879A1 (en) | Compositions and methods for using csf1r inhibitors csf1r | |
| EP2742154A4 (en) | Biomarker compositions and methods | |
| EP2721179A4 (en) | Biomarker compositions and methods | |
| HK1202625A1 (en) | Compositions and methods for assessing appendicitis | |
| ZA201306316B (en) | Methods and compositions for preparing noribogaine from voacangine | |
| EP2691397A4 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| HK1201469A1 (en) | Compositions and methods for hemostasis | |
| ZA201307187B (en) | Synergistic compositions and methods | |
| EP2672822A4 (en) | Methods and compositions for improving cognitive function | |
| GB201411762D0 (en) | Precoating methods and compositions | |
| EP2741823A4 (en) | Methods and compositions for improving sperm functionality | |
| EP2931280A4 (en) | Methods and compositions for inhibiting cnksr1 | |
| ZA201308892B (en) | Compositions and methods | |
| EP2766357A4 (en) | Meso-biliverdin compositions and methods | |
| EP2798327A4 (en) | Compositions and methods for sample preparation | |
| EP2665480A4 (en) | Pharmaceutical compositions and methods for making and using them | |
| HK1174328A1 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| GB201116340D0 (en) | Compositions and methods | |
| IL230868A0 (en) | Biomarker compositions and methods | |
| IL228723B (en) | Synergistic compositions and methods | |
| GB201122124D0 (en) | Compositions and methods for treating biofilms | |
| GB201104584D0 (en) | Compositions and methods for treating biofilms |